The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
LONG-TERM BENEFIT OF 5-AMINOLEVULINIC ACID FLUORESCENCE ASSISTED TRANSURETHRAL RESECTION OF SUPERFICIAL BLADDER CANCER: 5-YEAR RESULTS OF A PROSPECTIVE RANDOMIZED STUDY
Abstract
PURPOSE: As shown in various studies 5-aminolevulinic acid (ALA) induces fluorescence of malignant and dysplastic bladder tissue and increases tumor detection rates by about 20%. However, data on the long-term benefits are sparse. Thus, the 5-year outcome data of a prospective randomized trial comparing patients who initially underwent bladder tumor resection (TUR) under standard white light or with ALA induced fluorescence were evaluated. MATERIALS AND METHODS: A total of 115 patients with suspected superficial bladder cancer were randomized to undergo standard or ALA assisted TUR. After the second look TUR at 6 weeks patients were followed for a median of 39 (standard) and 42 (ALA) months. RESULTS: Median time to first recurrence was 5 months in the standard and 12 months in the ALA group. Recurrence-free survival was 25% in the standard and 41% in the ALA group. The recurrence rate at 2, 12, 36 and 60 months after initial TUR was 41%, 61%, 73% and 75%, and 16%, 43%, 59% and 59% in the white light and ALA groups, respectively. The total number of recurrences was 82 in the standard and 61 in the ALA group. Tumor progression occurred in 9 patients in the standard and 4 in the ALA group. Cost analysis suggests a considerable economical advantage of ALA fluorescence assisted TUR compared to the standard procedure. CONCLUSIONS: The initial advantage of improved tumor detection and decreased recurrence rates by ALA fluorescence assisted TUR is maintained for years, and effectively reduces morbidity and costs in patients with superficial bladder tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Koenig, F., McGovern, F. J., Larne, R., Enquist, H., Schomacker, K. T., & Deutsch, T. F. (1999) · BJU International · doi:10.1046/j.1464-410x.1999.00917.x · Cited by 129
Self-citation
Cited by
Economic aspects of bladder cancer: what are the benefits and costs?
Sievert, K. D., Amend, B., Nagele, U., Schilling, D., Bedke, J., Horstmann, M., Hennenlotter, J., Kruck, S., & Stenzl, A. (2009) · World Journal of Urology · doi:10.1007/s00345-009-0395-z · Cited by 484
5-ALA and FDA Approval for Glioma Surgery
Hadjipanayis, C. G., & Stummer, W. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03098-y · Cited by 338
Mowatt, G., Zhu, S., Kilonzo, M., Boachie, C., Fraser, C., Griffiths, T., N'Dow, J., Nabi, G., Cook, J., & Vale, L. (2010) · Health Technology Assessment · doi:10.3310/hta14040 · Cited by 313
Kausch, I., Sommerauer, M., Montorsi, F., Stenzl, A., Jacqmin, D., Jichlinski, P., Jocham, D., Ziegler, A., & Vonthein, R. (2010) · European Urology · doi:10.1016/j.eururo.2009.11.041 · Cited by 313
Stenzl, A., Burger, M., Fradet, Y., Mynderse, L. A., Soloway, M. S., Witjes, J. A., Kriegmair, M., Karl, A., Shen, Y., & Grossman, H. B. (2010) · Journal of Urology · doi:10.1016/j.juro.2010.06.148 · Cited by 304
Metadata
- Authors
- DANILTCHENKO, D. I., RIEDL, C. R., SACHS, M. D., KOENIG, F., DAHA, K. L., PFLUEGER, H., LOENING, S. A., & SCHNORR, D.
- Venue
- Journal of Urology
- Published
- 2005-12
- Volume
- 174
- Issue
- 6
- Pages
- 2129-2133
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2162395412
- Cited by
- 198
- References
- 1
- FWCI
- 7.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: LONG-TERM BENEFIT OF 5-AMINOLEVULINIC ACID FLUORESCENCE ASSISTED TRANSURETHRAL RESECTION OF SUPERFICIAL BLADDER CANCER: 5-YEAR RESULTS OF A PROSPECTIVE RANDOMIZED STUDY. https://app.cochat.ai/papers/10.1097/01.ju.0000181814.73466.14
- The paper
- DANILTCHENKO, D. I., RIEDL, C. R., SACHS, M. D., KOENIG, F., DAHA, K. L., PFLUEGER, H., LOENING, S. A., & SCHNORR, D. (2005). LONG-TERM BENEFIT OF 5-AMINOLEVULINIC ACID FLUORESCENCE ASSISTED TRANSURETHRAL RESECTION OF SUPERFICIAL BLADDER CANCER: 5-YEAR RESULTS OF A PROSPECTIVE RANDOMIZED STUDY. Journal of Urology. https://doi.org/10.1097/01.ju.0000181814.73466.14
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.